Who owns INOZYME PHARMA INC?
- Ticker: INZY
- CUSIP Number: 45790w108
Tip: Access positions for across all investors
Analyze quarterly positions in Inozyme Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Inozyme Pharma stock
Who bought or sold INOZYME PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Adage Capital Partners GP | 5.3M | $41M | -4% | Mar 2024 |
|
| Sofinnova Ventures | 4.3M | $33M | 0% | Mar 2024 |
|
| Rock Springs Capital Management | 3.7M | $28M | 0% | Mar 2024 |
|
| Eventide Asset Management | 3.2M | $24M | 0% | Mar 2024 |
|
| BlackRock | 3.1M | $24M | 38% | Mar 2024 |
|
| Samlyn Capital | 2.9M | $22M | -14% | Mar 2024 |
|
| NEA Management Company | 2.4M | $19M | 0% | Mar 2024 |
|
| Vanguard Group | 2.4M | $19M | 1% | Mar 2024 |
|
| FMR | 2.0M | $15M | -20% | Mar 2024 |
|
| Samsara BioCapital | 1.6M | $12M | 0% | Mar 2024 |
|
| Sphera Funds Management | 1.4M | $11M | -12% | Mar 2024 |
|
| Blue Owl Capital Holdings | 1.3M | $9.7M | 0% | Mar 2024 |
|
| Geode Capital Management | 1.1M | $8.2M | 30% | Mar 2024 |
|
| Woodline Partners | 888k | $6.8M | 100% | Mar 2024 |
|
| Millennium Management | 704k | $5.4M | -23% | Mar 2024 |
|
| Kennedy Capital Management | 438k | $3.4M | 52% | Mar 2024 |
|
| Northern Trust | 420k | $3.2M | 25% | Mar 2024 |
|
| Goldman Sachs Group | 410k | $3.1M | 13% | Mar 2024 |
|
| Laurion Capital Management | 402k | $3.1M | -28% | Mar 2024 |
|
| Exome Asset Management | 273k | $2.1M | 100% | Mar 2024 |
|
| Parkman Healthcare Partners | 223k | $1.7M | 27% | Mar 2024 |
|
| Overbrook Management Corp. | 219k | $1.7M | 0% | Mar 2024 |
|
| UBS O'Connor | 183k | $1.4M | 100% | Mar 2024 |
|
| Dimensional Fund Advisors | 175k | $1.3M | 174% | Mar 2024 |
|
| Bank of New York Mellon | 164k | $1.3M | 4% | Mar 2024 |
|
| Nuveen Asset Management | 161k | $1.2M | 17% | Mar 2024 |
|
| GSA Capital Partners | 131k | $1.0M | -22% | Mar 2024 |
|
| Charles Schwab Investment Management | 127k | $969k | 4% | Mar 2024 |
|
| Morgan Stanley | 124k | $952k | 371% | Mar 2024 |
|
| Superstring Capital Management | 113k | $864k | -9% | Mar 2024 |
|
| Citadel Advisors | 100k | $768k | -43% | Mar 2024 |
|
| Schonfeld Strategic Advisors | 75k | $573k | -31% | Mar 2024 |
|
| Rhumbline Advisers | 63k | $484k | 5% | Mar 2024 |
|
| Springbok Capital Management | 62k | $478k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 62k | $472k | 79% | Mar 2024 |
|
| Bank of America Corporation | 60k | $459k | -24% | Mar 2024 |
|
| American Century Companies | 51k | $394k | 185% | Mar 2024 |
|
| UBS Group | 48k | $367k | 4% | Mar 2024 |
|
| Susquehanna International | 46k | $354k | -82% | Mar 2024 |
|
| ALPS Advisors | 42k | $180k | 100% | Dec 2023 |
|
| Two Sigma Advisers | 41k | $316k | -42% | Mar 2024 |
|
| Barclays | 37k | $282k | -47% | Mar 2024 |
|
| Connor, Clark & Lunn Investment Management | 35k | $267k | 100% | Mar 2024 |
|
| Balyasny Asset Management | 31k | $240k | 100% | Mar 2024 |
|
| Two Sigma Investments | 30k | $229k | -44% | Mar 2024 |
|
| Jane Street | 29k | $223k | -43% | Mar 2024 |
|
| AQR Capital Management | 28k | $212k | -40% | Mar 2024 |
|
| MetLife Investment Advisors | 27k | $113k | 47% | Dec 2023 |
|
| Bailard | 24k | $186k | 100% | Mar 2024 |
|
| American International | 24k | $101k | 40% | Dec 2023 |
|
| Denali Advisors | 22k | $169k | 0% | Mar 2024 |
|
| Alliancebernstein | 18k | $78k | 0% | Dec 2023 |
|
| Bridgeway Capital Management | 18k | $136k | -81% | Mar 2024 |
|
| Lido Advisors | 17k | $131k | 100% | Mar 2024 |
|
| Wells Fargo & Company | 17k | $129k | 15% | Mar 2024 |
|
| Parallel Advisors | 16k | $123k | 0% | Mar 2024 |
|
| Ing Investment Management | 16k | $122k | 16% | Mar 2024 |
|
| Deutsche Bank Aktiengesellschaft | 15k | $118k | -5% | Mar 2024 |
|
| T. Rowe Price Associates | 14k | $109k | 12% | Mar 2024 |
|
| SG Americas Securities | 14k | $107k | -34% | Mar 2024 |
|
| Resources Investment Advisors | 14k | $105k | 100% | Mar 2024 |
|
| New York State Common Retirement Fund | 13k | $102k | 0% | Mar 2024 |
|
| Citigroup | 9.0k | $69k | 34% | Mar 2024 |
|
| Summit Investment Advisors | 4.8k | $37k | 0% | Mar 2024 |
|
| California State Teachers Retirement System | 4.8k | $37k | -36% | Mar 2024 |
|
| Legal & General Group | 4.0k | $31k | 0% | Mar 2024 |
|
| Metropolitan Life Insurance Company | 2.9k | $12k | 54% | Dec 2023 |
|
| Royal Bank of Canada | 2.0k | $15k | -87% | Mar 2024 |
|
| Group One Trading | 1.2k | $9.0k | 17% | Mar 2024 |
|
| Amalgamated Bank | 1.1k | $9.0k | -61% | Mar 2024 |
|
| BFSG | 500.00 | $3.8k | 100% | Mar 2024 |
|
| Tower Research Capital | 398.00 | $3.0k | -95% | Mar 2024 |
|
| Simplex Trading | 168.00 | $1.0k | 100% | Mar 2024 |
|
| Signature | 113.00 | $865.998100 | 100% | Mar 2024 |
|
| ICA Group Wealth Management | 85.00 | $650.998000 | 100% | Mar 2024 |
|
| Advisor Group Holdings | 50.00 | $383.000000 | 0% | Mar 2024 |
|
| GAMMA Investing | 48.00 | $368.001600 | 100% | Mar 2024 |
|
| NISA Investment Advisors | 24.00 | $184.000800 | 100% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 9.00 | $68.000400 | 100% | Mar 2024 |
|
| CWM | 3.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Inozyme Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Octagon Capital Advisors | Dec 2023 | 400k | $1.7M |
| MPM Oncology Impact Management | Sep 2023 | 327k | $1.4M |
| Virtu Financial | Dec 2023 | 27k | $114k |
| Bank Of Montreal | Dec 2023 | 22k | $99k |
| Values First Advisors | Dec 2023 | 14k | $59k |
| Florida State Board of Administration | Dec 2023 | 12k | $53k |